CEL-SCI (CVM) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

CVM CEL-SCI

Watchlist

0.710
-0.027-3.70%

Trading Dec 13 12:08 ET

45.30MMarket Cap-1.22P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
BusinesswireDec 12 09:15 ET
Express News | Watching CEL-SCI; Zacks Small-Cap Research Gives Stock $7 Price Valuation
BenzingaDec 9 09:34 ET
Express News | CEL-SCI Corp: On November 13, Patricia B Prichep Has Assumed the Duties of Chief Financial and Operations Officer
ReutersNov 15 16:33 ET
CEL-SCI, FDA Agree on Patient Selection Approach for Multikine Study
TipRanksNov 7 09:25 ET
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
BusinesswireNov 7 08:15 ET
CEL-SCI Files to Sell 1M Shares of Common Stock for Holders
TipRanksOct 25 17:20 ET

Comments

Jaguar8

16 hours ago

🕗Watchlist FRIDAY December 13. NFA. Tired now so I’ll attach the watchlist for Thursday and Wednesday and check those which didn’t run yet. Remember it’s our lucky day tomorrow: Friday 13th

NOTE: Whenever a stock is up, make sure you check its dilution risk - cash on hand because most likely if they are cash-strapped, they will make offering. Scaling out is key. NEVER listen to those who say hold on because if you lose money, they wouldnt care AT ALL.
*************************************
REVERSE...

Jaguar8

Dec 12 08:22

NEWS

$CEL-SCI (CVM.US)$
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
Thursday, 12th December at 9:15 am
• Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery
• Factors supporting the go-ahead for the 212-person registration study in the target population include:
◦ Multikine led to significant rates of tumor reg...

Stock_Drift

Nov 26 04:28

Premarket Ticks. 5:27am 11/26

$VSee Health (VSEE.US)$ $CEL-SCI (CVM.US)$ $SmartKem (SMTK.US)$ $Volato Group (SOAR.US)$ $Onconetix (ONCO.US)$ $Fusion Fuel Green (HTOO.US)$ $SEALSQ Corp (LAES.US)$ $Semtech (SMTC.US)$ $HA Sustainable Infrastructure (HASI.US)$ $Spectral AI (MDAI.US)$ $T Stamp (IDAI.US)$ $ZenaTech (ZENA.US)$ $Poseida Therapeutics (PSTX.US)$

Trytosaveabit

Nov 7 07:17

News

$CEL-SCI (CVM.US)$ U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
2 MINUTES AGO, 8:15 AM EST
VIA BUSINESSWIRE
• Biomarker used to select patients who are more likely have favorable outcomes, supporting a successful confirmatory Registration Study
• Patients with low PD-L1 expression treated with Multikine in the target population had a 5-year survival of 73% vs. 45% in the control group in the...

Jaguar8

Nov 7 07:15

NEWS

$CEL-SCI (CVM.US)$
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
CEL-SCI (NYSE: CVM) announced FDA agreement on using PD-L1 biomarker for patient selection in its upcoming Multikine Registration Study for head and neck cancer, starting Q1 2025. The study will focus on patients with low PD-L1 tumor expression, following promising results from a previous Phase 3 study where patients showed 73% v...

Heat List

Overall

No Data

Investment Theme

Top Gainers Yesterday

Intraday-0.38%